{"id":"NCT00160693","sponsor":"UCB Pharma","briefTitle":"Open Label Long-Term Safety Study of Certolizumab Pegol (CZP) for Patients With Rheumatoid Arthritis","officialTitle":"A Phase III, Multicenter, Open-Label Long-Term Study to Assess the Safety and Tolerability of CDP870 400 mg Subcutaneously Every 4 Weeks, in Subjects With Rheumatoid Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2003-03","primaryCompletion":"2011-02","completion":"2011-02","firstPosted":"2005-09-12","resultsPosted":"2012-07-09","lastUpdate":"2018-08-01"},"enrollment":402,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"BIOLOGICAL","name":"Certolizumab Pegol","otherNames":["Cimzia"]}],"arms":[{"label":"Certolizumab Pegol","type":"EXPERIMENTAL"}],"summary":"The primary purpose of this study is to obtain long-term safety data with CZP in patients with Rheumatoid Arthritis (RA). Additional objectives are to assess the dose and type of Arthritis medication(s) utilized by patients, and to assess the long-term impact of CZP on physical function. Treatment will continue up to approval of a marketing application for this product.","primaryOutcome":{"measure":"Percentage of Subjects With at Least One Adverse Event (AE) During the Study Period of 8 Years","timeFrame":"From first dose of CZP up to 8 years","effectByArm":[{"arm":"Certolizumab Pegol","deltaMin":93.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":12},"locations":{"siteCount":61,"countries":["United States","Austria","Belgium","Czechia","Germany","Ireland","United Kingdom"]},"refs":{"pmids":["28353191"],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":184,"n":402},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Back pain","Headache","Urinary tract infection"]}}